Literatur
Dr. Bernhard .Heinrich Stand 1/2019
1. Nasifoglu S, Heinrich B, Welzel J. Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor. Br J Dermatol. 2018 Aug;179(2):504-505. doi: 10.1111/bjd.16468. Epub 2018 May 21. PubMed PMID: 29451690.
2. Peter A. Fasching, Arnd Nusch, Bernhard Heinrich, Sara Brucker, Thomas Decker, Christian M. Kurbacher, Hans Tesch, Petra Krabisch, Christoph Mundhenke, Tanja N. Fehm, Wolfgang Janni, Diana Lueftner, Andreas Schneeweiss, Martin H. Schuler, Gernot Guderian, Claudia Voges, Joerg Schubert, Sherko Kummel; RIBECCA: A phase IIIb, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole—Results of the first interim analysis. J Clin Oncol 36, 2018 (suppl; abstr 1051) Bernhard Heinrich, Richard F Schlenk, Olaf Lothar Brudler, Simone Edenhofer, Angelika Scheuerle, Ralph Naumann, Regine Mayer-Steinacker, Markus Bangerter, Lars Bullinger Activity of cabazitaxel in temozolomide refractory glioblastoma: Final results of a phase 2 study (C-GBM study; EudraCT 2013-001550-98 NCT 01866449 Clin Oncol 35, 2017 (suppl; abstr 2056)
3. Krackhardt AM, Heinrich B. [Progress in cancer immunotherapy]. MMW Fortschr Med. 2017 Aug;159(14):48-53. doi: 10.1007/s15006-017-9949-y. Review. German. PubMed PMID: 28924719.
4. Heigener DF, Schumann C, Sebastian M, Sadjadian P, Stehle I, Märten A, Lüers A, Griesinger F, Scheffler M(Studienteilnahme in der digitalen Version angeführt); Afatinib Compassionate Use Consortium (ACUC). Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors. Oncologist. 2015 Oct;20(10):1167-74. doi: 10.1634/theoncologist.2015-0073. Epub 2015 Sep 9. PubMed PMID: 26354527; PubMed Central PMCID: PMC4591955.
5. Heinrich B, Brudler O, Bangerter M. [Chemotherapy is better than its reputation: important developments within the last decades]. MMW Fortschr Med. 2015 Aug 20;157(14):39-43. doi: 10.1007/s15006-015-3417-3. Review. German. PubMed PMID: 26289884.
6. Heinrich B. [Cancer diagnosis: no need to despair]. MMW Fortschr Med. 2015 Aug 20;157(14):38. doi: 10.1007/s15006-015-3416-4. German. PubMed PMID: 26289883.
7. Heinrich B, Brudler O, Bangerter M. [HPV associated diseases: More than warts and cervical carcinoma]. MMW Fortschr Med. 2015 May 13;157(9):41-4. doi: 10.1007/s15006-015-3082-6. Review. German. PubMed PMID: 26012825.
8. Hoffknecht P, Tufman A, Wehler T, Pelzer T, Wiewrodt R, Schütz M, Serke M, Stöhlmacher-Williams J, Märten A, Maria Huber R, Dickgreber NJ; Afatinib Compassionate Use Consortium (ACUC) (Studienteilnahme in der digitalen Version angeführt) . Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol. 2015 Jan;10(1):156-63. doi: 10.1097/JTO.0000000000000380. PubMed PMID: 25247337; PubMed Central PMCID: PMC4276567.
9. Schuler M, Fischer JR, Grohé C, Gütz S, Thomas M, Kimmich M, Schneider CP, Laack E, Märten A; Afatinib Compassionate Use Consortium (Studienteilnahme in der digitalen Version angeführt). Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib. Oncologist. 2014 Oct;19(10):1100-9. doi: 10.1634/theoncologist.2014-0103. Epub 2014 Sep 17. PubMed PMID: 25232040; PubMed Central PMCID: PMC4200993.
10. Von Minckwitz G, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer JU, Hauschild M, Fehm T, Nekljudova V, Gerber B (Studienteilnahme in der digitalen Version angeführt); GBG/AGO-B study groups. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†. Ann Oncol. 2014 Dec;25(12):2363-72. doi: 10.1093/annonc/mdu455. Epub 2014 Sep 15. PubMed PMID: 25223482.
11. Heinrich B. [Skin cancer: it’s worth it to take a look!]. MMW Fortschr Med. 2014 Mar 6;156(4):36. German. PubMed PMID: 24908773.
12. Heinrich B. [New local therapies in lung cancer]. MMW Fortschr Med. 2013 Jul 25;155(13):37. German. PubMed PMID: 23964504.
13. Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M, Raab HR, Sülberg H, Wittekind C, Potapov S, Staib L, Hess C, Weigang-Köhler K, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R; German Rectal Cancer Study Group. (Studienteilnahme in der digitalen Version angeführt) Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012 Jul;13(7):679-87. doi: 10.1016/S1470-2045(12)70187-0. Epub 2012 May 23. PubMed PMID: 22627104.
14. Heinrich B. [Improve living with cancer]. MMW Fortschr Med. 2011 Dec 1;153(48):34. German. PubMed PMID: 22299255.
15. Heinrich B; Komitee für Praktische Onkologie. [Asbestos-induced diseases: an on-going problem]. MMW Fortschr Med. 2011 Jun 2;153(22):34. German. PubMed PMID: 21682031.
16. Heinrich B. [Not Available]. MMW Fortschr Med. 2011 Jun;153(22):34. doi: 10.1007/BF03368476. German. PubMed PMID: 27369021. 57
17. Mohty M, Terpos E, Mateos MV, Cavo M, Lejniece S, Beksac M, Bekadja MA, Legiec W, Dimopoulos M, Stankovic S, Durán MS, De Stefano V, Corso A, Kochkareva Y, Laane E, Berthou C, Salwender H, Masliak Z, Pečeliūnas V, Willenbacher W, Silva
J, Louw V, Nemet D, Borbényi Z, Abadi U, Pedersen RS, Černelč P, Potamianou A, Couturier C, Feys C, Thoret-Bauchet F, Boccadoro M(Studienteilnahme in der digitalen Version angeführt); EMMOS Investigators. Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):e401-e419. doi: 10.1016/j.clml.2018.06.018. Epub 2018 Jun 25. PubMed PMID: 30030033.
18. Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; (Studienteilnahme in der digitalen Version angeführt)ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13. PubMed PMID: 29146401.
19. Wiechno P, Somer BG, Mellado B, Chłosta PL, Cervera Grau JM, Castellano D, Reuter C, Stöckle M, Kamradt J, Pikiel J, Durán I, Wedel S, Callies S, André V, Hurt K, Brown J, Lahn M, Heinrich B. A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer. Eur Urol. 2014 Mar;65(3):516-20. doi: 10.1016/j.eururo.2013.10.039. Epub 2013 Nov 6. PubMed PMID: 24246407. A Randomised Phase 2 Study Combining LY2181308 Sodium (Survivin Antisense Oligonucleotide) with First-line Docetaxel/Prednisone in Patients with Castration-resistant Prostate Cancer Paweł Wiechno, Bradley G. Somer, Begoña Mellado, Piotr L. Chłosta, J.M. Cervera Grau, Daniel Castellano, Christoph Reuter, Michael Stöckle, Jörn Kamradt, Joanna Pikiel, Ignacio Durán, Steffen Wedel, Sophie Callies, Valérie André, Karla Hurt, Jacqueline Brown, Michael Lahn and Bernhard Heinrich
20. Dederke, B, Schumann C, Seraphin, Wagner, Rittmeyer, Eschenburg, Harich, Vehling-Kaiser, Esser, Heinrich B. Erlotinib in der Routinebehandlung des NSCLC nach Versagen einer vorangegangen Chemotherapie Poster Kongress Dt. Gesellschaft für Pneumonologie 2011 Dresden
21. Heinrich B. [Improve living with cancer]. MMW Fortschr Med. 2011 Dec 1;153(48):34. German. PubMed PMID: 22299255.
22. P. J. Wiechno, P. Chlosta, J. Smok-Kalwat, J. Pikilel, D. H. Henry, D. F. Christianson, B. G. Somer, B. Mellado, I. Duran, D. E. Castellano, S. Callies, V. Andre, K. Hurt, M. M. F. Lahn, M. Stöckle, C. Reuter, B. Heinrich; Interim results of a randomized phase II study with window-design to evaluate antitumor activity of the survivin antisense oligonucleotide (ASO) LY2181308 in combination with docetaxel for first-line treatment of castrate-resistant prostate cancer (CRPC).
23. 2011 ASCO Annual Meeting Abstract No: 4592 J Clin Oncol 29: 2011 (suppl; abstr 4592)
24. Heinrich B; Komitee für Praktische Onkologie. [Asbestos-induced diseases: an on-going problem]. MMW Fortschr Med. 2011 Jun 2;153(22):34. German. PubMed PMID: 21682031.
25. Heinrich B. [Adjuvant cancer therapy]. MMW Fortschr Med. 2010 Oct 14;152(41):36. German. PubMed PMID: 21090374.
26. Heinemann V, Di Gioia D, Vehling-Kaiser U, Harich HD, Heinrich B, Welt A, Ziske C, Deutsch G, Pihusch R, Kölbl H, Hegewisch-Becker S, Michl M, Stemmler HJ. A prospective multicenter phase II study of oral and i.v. vinorelbine plus
trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer. Ann Oncol. 2011 Mar;22(3):603-8. Epub 2010 Aug 19. PubMed PMID: 20724574.
27. Wbelitz KR, Beer AM, Heinrich B. [Mistletoe therapy in cancer treatment: pros and cons]. MMW Fortschr Med. 2009 Nov 12;151(46):30-1. German. PubMed PMID:20043390.
28. Heinrich B, Schrembs I, Brudler O, Bangerter M. [Anemia: from symptoms to diagnosis and therapy]. MMW Fortschr Med. 2009 Nov 26;151(48):31-5; quiz 36. Review. German. PubMed PMID: 20085059.
29. Dresemann G, Weller M, Rosenthal MA, Wedding U, Wagner W, Engel E, Heinrich B, Mayer-Steinacker R, Karup-Hansen A, Fluge O, Nowak A, Mehdorn M, Schleyer E, Krex D, Olver IN, Steinbach JP, Hosius C, Sieder C, Sorenson G, Parker R, Nikolova Z. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J Neurooncol. 2010 Feb;96(3):393-402. Epub 2009 Aug 18. PubMed PMID: 19688297.
30. Reimer G, Brudler O, Heinrich B, Bangerter M. [EGFR (epidermal growth factor receptor) inhibitor-associated skin disorders in tumor therapy]. MMW Fortschr Med. 2008 Dec 4;150(49-50):37-8, 40. German. PubMed PMID: 19133368.
31. Heinrich B. [Novel therapies in oncology: how about adverse effects?]. MMW Fortschr Med. 2008 Dec 4;150(49-50):32. German. PubMed PMID: 19130772.
32. Heinrich B. [Fever–a cardinal symptom in medicine] MMW Fortschr Med. 2008 Jan 17;150(1-2):46-50; quiz 51. Review. German. No abstract available. PMID: 18300646 [PubMed – indexed for MEDLINE]
33. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A,
Wilkowski R. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006 Aug 20;24(24):3946-52. PMID: 16921047 [PubMed – indexed for MEDLINE]
34. Bangerter M, Brudler O, Heinrich B, Schrembs I, Griesshammer M. Open or closed nuclear membrane? A question to help distinguish malignant lymphoma from carcinoma and sarcoma. Acta Cytol. 2008 Jan-Feb;52(1):52-5. PMID: 18323275 [PubMed – indexed for MEDLINE]
35. Heinrich B. [Counselling, treatment and aftercare of cancer patients by the family physician] MMW Fortschr Med. 2007 Sep 6;149(35-36):26. German. No abstract available. PMID: 17944280 [PubMed – indexed for MEDLINE]
36. Bangerter M, Brudler O, Heinrich B, Griesshamnuer M. Fine needle aspiration cytology and flow cytometry in the diagnosis and subclassification of non-Hodgkin’s lymphoma based on the World Health Organization classification. Acta Cytol. 2007 May-Jun;51(3):390-8.
37. PMID: 17536541 [PubMed – indexed for MEDLINE] Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast. 2006 Jul 15; [Epub ahead of print] PMID: 16026983 [PubMed – as supplied by publisher]
38. Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V. Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC). Onkologie. 2005 Nov;28(11):582-6. PMID: 16249644 [PubMed – indexed for MEDLINE]
39. Heinrich B. [Therapeutic outcomes in systemic lymphatic diseases and plasmacytoma. New hope for palliative patients] MMW Fortschr Med. 2005 Jun 16;147(24):23. German. No abstract available. PMID: 16001528 [PubMed – indexed for MEDLINE]
40. Stemmler, S. Kahlert, W. Siekiera, M. Untch, B. Heinrich, V. Heinemann: BRAIN METASTASES (BM) IN PATIENTS TREATED WITH TRASTUZUMAB FOR HER2 OVEREXPRESSING METASTATIC BREAST CANCER (MBC): INCIDENCE AND SURVIVAL ASCO 2005
41. Bangerter M, Heinrich B, Brudler O. [Medical treatment of cancer in the elderly] MMW Fortschr Med. 2004 Sep 30;146(40):30-2. Review. German. PMID: 15529665 [PubMed – indexed for MEDLINE]
42. Hausmaninger H, Morack G, Heinrich B, Wallwiener D, Hoffken K, Buksmaui S, Krejcy K, Miller MA, Possinger K. Gemcitabine combined with epirubicin in the treatment of patients with locally advanced or metastatic breast cancer: a phase II study. Am J Clin Oncol. 2004 Aug;27(4):429-35. PMID: 15289740 [PubMed – indexed for MEDLINE]
43. Gelmon KA, Mackey J, Verma S, Gertler SZ, Bangemann N, Klimo P, Schneeweiss A, Bremer K, Soulieres D, Tonkin K, Bell R, Heinrich B, Grenier D, Dias R. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer. 2004 Apr;5(1):52-8; discussion 59-62. PMID: 15140285 [PubMed – indexed for MEDLINE]
44. B. Heinrich, O. Brudler, W. Siekiera, G. Raab, V. Heinemann: Development of brain metastasis in metastatic breast cancer (MBC) responding to treatment with trastuzumab Proc Am Soc Clin Oncol 22: page 37, 2003 (abstr 147
45. Schellens JH, Heinrich B, Lehnert M, Gore ME, Kaye SB, Dombernowsky P, Paridaens R, van Oosterom AT, Verweij J, Loos WJ, Calvert H, Pavlidis N, Cortes-Funes H, Wanders J, Roelvink M, Sessa C, Selinger K, Wissel PS, Gamucci T, Hanauske AR. Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies. Invest New Drugs. 2002 Feb;20(1):83-93. PMID: 12003197 [PubMed – indexed for MEDLINE]
46. Gamucci T, Paridaens R, Heinrich B, Schellens JH, Pavlidis N, Verweij J, Sessa C, Kaye S, Roelvink M, Wanders J, Hanauske A. Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study. Ann Oncol. 2000 Jul;11(7):793-7. PMID: 10997805 [PubMed – indexed for MEDLINE]
47. Hesse K, Heinrich B, Zimmermann F, Kau R, Sommer G, Achterrath W, Molls M, Feldmann HJ. Combined radiochemotherapy with docetaxel in patients with unresectable locally advanced head and neck tumors. Strahlenther Onkol. 2000 Feb;176(2):67-72. PMID: 10697653 [PubMed – indexed for MEDLINE]
48. Thodtmann F, Theiss F, Kemmerich M, Heinrich B, Laubenbacher C, Quasthoff S, Kau R, Herzog M, Diergarten K, Hanauske AR. Clinical phase II evaluation of paclitaxel in combination with cisplatin in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol. 1998 Mar;9(3):335-7. PMID: 9602270 [PubMed – indexed for MEDLINE]
49. Hanauske AR, Korfel A, Perker M, Heinrich B, Schwab G, Graf M, Depenbrock H, Hoffken G, Kreuser ED, Thiel E, Zwingers T, Berdel WE. Dose intensity phase I/II trial with carboplatin, ifosfamide, etoposide and vincristine combined with filgrastim in patients with small-cell lung cancer. Oncology. 1997 Sep-Oct;54(5):363-70. PMID: 9260596 [PubMed – indexed for MEDLINE]
50. Schilling T, Heinrich B, Kau R, Herzog M, Quasthoff S, Diergarten K, Rastetter J, Hanauske AR. Paclitaxel administered over 3 h followed by cisplatin in patients with advanced head and neck squamous cell carcinoma: a clinical phase I study.
Oncology. 1997 Mar-Apr;54(2):89-95. PMID: 9075777 [PubMed – indexed for MEDLINE]
51. B Heinrich, M Lehnert, F Cavalli, N Pavlidis, J Wanders, AR Hanauske: Phase II trial of GI 147211 in locally advanced or metastatic non-small cell lung cancer (NSCLC): an EORTC-ECSG trial (Meeting abstract). 1997 ASCO Annual Meeting
52. R Thodtmann, S Smith, W Romer, U Muller, B Heinrich, H Depenbrock, J Rizzo, von Hoff DD, H Dietzfelbinger, J Rastetter, AR Hanauske: Phase I study of CHOP/MGBG (CM) in patients with non-Hodgkin’s lymphoma (Meeting abstract). 1997 ASCO Annual Meeting
53. McLeod HL, Murray LS, Wanders J, Setanoians A, Graham MA, Pavlidis N, Heinrich B, ten Bokkel Huinink WW, Wagener DJ, Aamdal S, Verweij J. Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups. Br J Cancer. 1996 Dec;74(12):1944-8. PMID: 8980394 [PubMed – indexed for MEDLINE]
54. Kaplan S, Hanauske AR, Pavlidis N, Bruntsch U, te Velde A, Wanders J, Heinrich B, Verweij J. Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group. Br J Cancer. 1996 Feb;73(3):403-5. PMID: 8562351 [PubMed – indexed for MEDLINE]
55. Schilling T, Fiebig HH, Kerpel-Fronius S, Winterhalter B, Variol P, Tresca P, Heinrich B, Hanauske AR. Clinical phase I and pharmacokinetic trial of vinorelbine administered as single intravenous bolus every 21 days in cancer patients. Invest New Drugs. 1996;14(4):371-8. PMID: 9157072 [PubMed – indexed for MEDLINE]
56. M. Perker, A. R. Hanauske, A.R. Korfel, G. Schwob, M. Graf, Th Zwingers, B. Heinrich, J. Rastetter, G. Hoeffken, E.D. Kreuser, E. Thiel, W.E. Berdel, Dose Intensification of CEV-Ifo with R-MethUG-CSF (Filgrastim) support in patients with SCLC- A dose intensification trial AIO Symposion Jan 1996 Berlin, Oncology
57. A.R. Hanauske, T. Schilling, B. Heinrich, Kau.R., Herzog, M. Quasthoff, S. Diergarten K. Rastetter, J. Clinical Phase II study of paclitaxel followed by cisplatin in patients with recurrent head and neck cancer Proc. Am. Assoc. Canc. Res. Vol 37: 168 1996
58. A. R. Hanauske, H. Depenbrock, B. Heinrich: Prophylactic cranial radiation in patients with small cell lung cancer: still an open question? Crit Rev Neurosurg : 106 – 107 1996
59. J. Wanders, W:W. tan Bokkel Huinink, B. Heinrich, M. Gore. A.H. Calvert, M. Lahnert, A. te Velde, J. Verweij on behalf of EORTC-ECSG and EORTC-NDDO Phase II studies with GI-147211 in 5 different tumor types -prelimnary results
NCI-EORTC Symposium Amsterdam 1996,
60. P Schoffski, J Wanders, G Catimel, B Heinrich, D Schrijvers, M Gore, D Oulid-Aissa, J Verweij 1996 ASCO Annual Meeting Docetaxel and cisplatin: a highly active regimen for squamous cell carcinoma of the head and neck (Meeting abstract
61. Hanauske AR, Schilling T, Heinrich B, Kau R, Herzog M, Quasthoff S, Bochtler H, Diergarten K, Rastetter J. Clinical phase I study of paclitaxel followed by cisplatin in advanced head and neck squamous cell carcinoma.Semin Oncol. 1995 Dec;22(6 Suppl 14):35-9. PMID: 8553082 [PubMed – indexed for MEDLINE]
62. Heinrich B.; Fromm M.; Rastetter J.; Hanauske A.R.: Neue Aspekte in der Therapie des nicht-kleinzelligen Bronchialkarzinoms Der Mediziner 4, 64-68,1995
63. Bruntsch U, Heinrich B, Kaye SB, de Mulder PH, van Oosterom A, Paridaens R, Vermorken JB, Wanders J, Franklin H, Bayssas M, et al. Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group.
Eur J Cancer. 1994;30A(8):1064-7. PMID: 7654430 [PubMed – indexed for MEDLINE]
64. Heinrich B, Strauß, S.; Fromm, M.; Perker, M.; Schick, H.; Fink, U.; Rastetter, J.; Hanauske, A.-R.: Clinical phase II study of high-dose ifosfamide in patients with advanced soft tissue sarcoma J Cancer Res Clin Oncol 120 (suppl), 27 (1994)
65. Hanauske, A.-R., Korfel, A.; Perker, M.; Schwab, G.; Zwingers, Th.; Heinrich; B.; Rastetter, J.; Kreuser, E.-D.; Thiel, E.; Berdel, W.-F.: A pilot dose intensification trial with carboplatin, etoposid, vincristine and ifosfamide (CEV-Ifo) with r-Met-u-G-CSF (filgrastim) support in patients with SCLC J Cancer Res Clin Oncol 120 (suppl), 22 (1994)
66. Depenbrock, H.; Strahlhuber, B.; Heinrich, B.; Rotter, M.; Lehmer, A.; Nekarda, J.; Rastetter, J. and Hanauske A.-R.: Preclinical activity of combinations of hematological growth factors on freshly explanted human tumor colony forming units Ann Hematol 66, Suppl. II, A 86 (1993)
67. Goebel FD, Bogner JR, Matuschke A, Heinrich B, Kronawitter U. Effects of granulocyte-colony-stimulating factor in neutropenic AIDS-patients. J Nutr Sci Vitaminol (Tokyo). 1992; Spec No:357-60. No abstract available. PMID: 1284306 [PubMed – indexed for MEDLINE]
68. Scheidegger C, Heinrich B, Popescu M, Gerhartz H, Eichenlaub D, Goebel FD, Kaboth W, Nerl C. [HIV-associated lymphomas] Dtsch Med Wochenschr. 1991 Jul 26;116(30):1129-35. German. PMID: 1855444 [PubMed – indexed for MEDLINE]
69. Wolff-Kormann PG, Hasenfratz BC, Heinrich B, Kormann B. Successful treatment with hydroxyurea of ocular involvement in chronic myelomonocytic leukemia. N Engl J Med. 1991 Jul 18;325(3):209-10. No abstract available. PMID: 2052066 [PubMed – indexed for MEDLINE]
70. Bogner JR, Gathof B, Heinrich B, Matuschke A, Backer U, Goebel FD. Erythrocyte antibodies in AIDS are associated with mycobacteriosis and hypergammaglobulinemia. Klin Wochenschr. 1990 Nov 9;68(21):1050-3. PMID: 2084318 [PubMed – indexed for MEDLINE]
v71. Bogner JR, Matuschke A, Heinrich B, Schreiber MA, Nerl C, Goebel FD. Expansion of activated T lymphocytes (CD3 + HLA/DR +) detectable in early stages of HIV-1 infection. Klin Wochenschr. 1990 Apr 17;68(8):393-6. PMID: 1971856 [PubMed – indexed for MEDLINE]
72. Gross M, Permanetter W, Heinrich B. [Burkitt’s lymphoma in HIV infection] Dtsch Med Wochenschr. 1990 Feb 23;115(8):295-9. Review. German. PMID: 2407485 [PubMed – indexed for MEDLINE]
73. Heinrich B, Gross M, Goebel FD. Methimazole-induced agranulocytosis and granulocyte-colony stimulating factor. Ann Intern Med. 1989 Oct 1;111(7):621-2. No abstract available. PMID: 2672934 [PubMed – indexed for MEDLINE]
74. Pfister HW, Einhaupl KM, Wick M, Fateh-Moghadam A, Huber M, Schielke E, Goebel FD, Matuschke A, Heinrich B, Bogner JR, et al. Myelin basic protein in the cerebrospinal fluid of patients infected with HIV. J Neurol. 1989 Jul;236(5):288-91. PMID: 2474637 [PubMed – indexed for MEDLINE]
75. Fuessl HS, Zoller WG, Kochen MM, Bogner JR, Heinrich B, Matuschke A, Goebel FD. Treatment of secretory diarrhea in AIDS with the somatostatin analogue SMS 201-995. Klin Wochenschr. 1989 Apr 17;67(8):452-5. PMID: 2724869 [PubMed – indexed for MEDLINE]
76. Bogner JR, Matuschke A, Heinrich B, Eberle E, Goebel FD. Serum neopterin levels as predictor of AIDS. Klin Wochenschr. 1988 Oct 17;66(20):1015-8. PMID: 2467041 [PubMed – indexed for MEDLINE]